Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from MapLight Therapeutics, Inc. ( (MPLT) ) is now available.
On April 23, 2026, MapLight Therapeutics, Inc. announced that board members Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., informed the board they will not stand for reelection at the annual meeting of stockholders scheduled for June 23, 2026. To maintain board continuity and expertise, the board nominated industry executives Martin Babler and Troy Cox as Class I director candidates to replace them, with the company emphasizing that the outgoing directors’ decisions were not driven by any dispute over its operations, policies or practices.
The board transition signals an orderly refresh of MapLight Therapeutics’ governance structure rather than a reaction to internal conflict, suggesting continued strategic stability for investors and other stakeholders. By bringing in Babler and Cox, the company appears to be reinforcing its leadership bench with seasoned industry experience at a time when board composition can influence investor confidence and oversight of its biopharmaceutical development programs.
The most recent analyst rating on (MPLT) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.
Spark’s Take on MPLT Stock
According to Spark, TipRanks’ AI Analyst, MPLT is a Neutral.
The score is driven primarily by mixed financials: a strong, low-debt balance sheet is offset by accelerating losses and cash burn. Technicals add support via a clear uptrend, while valuation is constrained by negative earnings and no dividend. A recent corporate update is positive due to cash runway and upcoming clinical catalysts, but higher spending remains a key risk.
To see Spark’s full report on MPLT stock, click here.
More about MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapies based on neuroscience and brain circuitry. The company operates in the life sciences sector, advancing drug candidates that target neurological and neuropsychiatric conditions for patients and healthcare providers in specialized therapeutics markets.
Average Trading Volume: 244,125
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.3B
See more data about MPLT stock on TipRanks’ Stock Analysis page.